AZT exerts its antitumoral effect by telomeric and non-telomeric effects in a mammary adenocarcinoma model

Armando,Romina   G.; Gomez,Diego  Mengual; Gomez,Daniel   E.

doi:10.3892/or.2016.5094

AZT exerts its antitumoral effect by telomeric and non-telomeric effects in a mammary adenocarcinoma model

Authors:
- Romina G. Armando
- Diego Mengual Gomez
- Daniel E. Gomez
View Affiliations

Affiliations: Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Bernal 1876, Buenos Aires, Argentina
Published online on: September 15, 2016 https://doi.org/10.3892/or.2016.5094
Pages: 2731-2736

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Limitless replicative potential is one of the hallmarks of cancer that is mainly due to the activity of telomerase. This holoenzyme maintains telomere length, adding TTAGGG repetitions at the end of chromosomes in each cell division. In addition to this function, there are extratelomeric roles of telomerase that are involved in cancer promoting events. It has been demonstrated that TERT, the catalytic component of telomerase, acts as a transcriptional modulator in many signaling pathways. Taking into account this evidence and our experience on the study of azidothymidine (AZT) as an inhibitor of telomerase activity, the present study analyzes the effect of AZT on some telomeric and extratelomeric activities. To carry out the present study, we evaluated the transcription of genes that are modulated by the Wnt/β-catenin pathway, such as c-Myc and cyclin-D1 (Cyc-D1) and cell processes related with their expression, such as, proliferation, modifications of the actin cytoskeleton, cell migration and cell cycle in a mammary carcinoma cell line (F3II). Results obtained after treatment with AZT (600 µM) for 15 passages confirmed the inhibitory effect on telomerase. Regarding extratelomeric activities, our results showed a decrease of 64, 38 and 25% in the transcription of c-Myc, Cyc-D1 and TERT, respectively (p<0.05) after AZT treatment. Furthermore, we found an effect on cell migration, reaching an inhibition of 48% (p<0.05) and a significant passage-dependent increase on cell doubling time during treatment. Finally, we evaluated the effect on cell cycle, obtaining a decline in G0/G1 in AZT-treated cells. These results allow us to postulate that AZT is not only an inhibitor of telomerase activity, but also a potential modulator of extratelomeric processes involved in cancer promotion.

View Figures

View References

1	Teralı K and Yilmazer A: New surprises from an old favourite: The emergence of telomerase as a key player in the regulation of cancer stemness. Biochimie. 121:170–178. 2016. View Article : Google Scholar
2	Martínez P and Blasco MA: Replicating through telomeres: A means to an end. Trends Biochem Sci. 40:504–515. 2015. View Article : Google Scholar : PubMed/NCBI
3	Gomez DE, Armando RG, Farina HG, Menna PL, Cerrudo CS, Ghiringhelli PD and Alonso DF: Telomere structure and telomerase in health and disease (Review). Int J Oncol. 41:1561–1569. 2012.PubMed/NCBI
4	Hájek M, Matulová N, Votruba I, Holý A and Tloust'ová E: Inhibition of human telomerase by diphosphates of acyclic nucleoside phosphonates. Biochem Pharmacol. 70:894–900. 2005. View Article : Google Scholar : PubMed/NCBI
5	Gomez D, Kassim A and Olivero O: Preferential incorporation of 3′-azido-2′,3′-dideoxythymidine (azt) in telomeric sequences of cho cells. Int J Oncol. 7:1057–1060. 1995.PubMed/NCBI
6	Gomez DE, Tejera AM and Olivero OA: Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment. Biochem Biophys Res Commun. 246:107–110. 1998. View Article : Google Scholar : PubMed/NCBI
7	Tejera AM, Alonso DF, Gomez DE and Olivero OA: Chronic in vitro exposure to 3′-azido-2′, 3′-dideoxythymidine induces senescence and apoptosis and reduces tumorigenicity of metastatic mouse mammary tumor cells. Breast Cancer Res Treat. 65:93–99. 2001. View Article : Google Scholar : PubMed/NCBI
8	Koh CM, Khattar E, Leow SC, Liu CY, Muller J, Ang WX, Li Y, Franzoso G, Li S, Guccione E, et al: Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J Clin Invest. 125:2109–2122. 2015. View Article : Google Scholar : PubMed/NCBI
9	Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, et al: Telomerase modulates Wnt signalling by association with target gene chromatin. Nature. 460:66–72. 2009. View Article : Google Scholar : PubMed/NCBI
10	Martínez P and Blasco MA: Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer. 11:161–176. 2011. View Article : Google Scholar : PubMed/NCBI
11	De Leonardis F, Monti L, Gualeni B, Tenni R, Forlino A and Rossi A: Altered signaling in the G1 phase deregulates chondrocyte growth in a mouse model with proteoglycan undersulfation. J Cell Biochem. 115:1779–1786. 2014. View Article : Google Scholar : PubMed/NCBI
12	Li Y, Casey SC and Felsher DW: Inactivation of MYC reverses tumorigenesis. J Intern Med. 276:52–60. 2014. View Article : Google Scholar : PubMed/NCBI
13	Alonso DF, Farías EF, Urtreger A, Ladeda V, Vidal MC and Bal De Kier Joffé E: Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. J Surg Oncol. 62:288–297. 1996. View Article : Google Scholar : PubMed/NCBI
14	Segatori VI, Otero LL, Fernandez LE, Gomez DE, Alonso DF and Gabri MR: Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides. In Vivo. 26:609–617. 2012.PubMed/NCBI
15	Chen YY, Wu XQ, Tang WJ, Shi JB, Li J and Liu XH: Novel dihydropyrazole-chromen: Design and modulates hTERT inhibition proliferation of MGC-803. Eur J Med Chem. 110:65–75. 2016. View Article : Google Scholar : PubMed/NCBI
16	Gomez DE, Armando RG and Alonso DF: AZT as a telomerase inhibitor. Front Oncol. 2:1132012. View Article : Google Scholar : PubMed/NCBI
17	Ji HJ, Rha SY, Jeung HC, Yang SH, An SW and Chung HC: Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res Treat. 93:227–236. 2005. View Article : Google Scholar : PubMed/NCBI
18	Jin RR, Chao R, Xi YM, Chen C, Chu HY, Li M and Zhang H: Effects of AZT on leukemia cell line KG-1a proliferation and telomerase activity. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 20:277–281. 2012.PubMed/NCBI
19	Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O and Nicot C: Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. 108:1021–1029. 2006. View Article : Google Scholar : PubMed/NCBI
20	Fang JL, McGarrity LJ and Beland FA: Interference of cell cycle progression by zidovudine and lamivudine in NIH 3T3 cells. Mutagenesis. 24:133–141. 2009. View Article : Google Scholar :
21	Olivero OA, Tejera AM, Fernandez JJ, Taylor BJ, Das S, Divi RL and Poirier MC: Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 20:139–146. 2005. View Article : Google Scholar : PubMed/NCBI
22	Bretones G, Delgado MD and León J: Myc and cell cycle control. Biochim Biophys Acta. 1849:506–516. 2015. View Article : Google Scholar
23	Hassani S, Ghaffari SH, Zaker F, Mirzaee R, Mardani H, Bashash D, Zekri A, Yousefi M, Zaghal A, Alimoghaddam K, et al: Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest. Ann Hematol. 92:1207–1220. 2013. View Article : Google Scholar : PubMed/NCBI
24	Abbas T and Dutta A: p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV, Prochownik EV and Nikiforov MA: c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene. 27:1905–1915. 2008. View Article : Google Scholar
26	Chen D, Huang J, Zhang K, Pan B, Chen J, De W, Wang R and Chen L: MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur J Cancer. 50:3050–3067. 2014. View Article : Google Scholar : PubMed/NCBI
27	Shi JW, Liu W, Zhang TT, Wang SC, Lin XL, Li J, Jia JS, Sheng HF, Yao ZF, Zhao WT, et al: The enforced expression of c-Myc in pig fibroblasts triggers mesenchymal-epithelial transition (MET) via F-actin reorganization and RhoA/Rock pathway inactivation. Cell Cycle. 12:1119–1127. 2013. View Article : Google Scholar : PubMed/NCBI
28	Bhushan B and Kush L: Pharmocophoric studies of anti-telomerase drugs. Int J Innov Res Dev. 3:268–272. 2014.